Nivata IPO Market Data
Acme Universal Safezone 9
IPO GMP & Details
Check Acme Universal Safezone 9 IPO GMP and its recorded history, price band, issue dates, total subscription, lot size and listing date. Unofficial GMP is not a listing forecast.
At a glance
Acme Universal Safezone 9 IPO details
Unofficial market context
Acme Universal Safezone 9 IPO GMP trend
The chart shows recent GMP movement over time. GMP is unofficial and should not be treated as a listing-price forecast or recommendation.
Latest chart observation+₹11
Change across recorded history+₹4
Recorded observations3
Current GMP reference price₹82
+₹11+₹7
1 Oct2 Oct
| Observation | GMP | Change | Reference price |
|---|---|---|---|
| 2 Oct 2026, 11:35 AM | +₹11 | ₹0 | ₹82 |
| 1 Oct 2026, 11:29 PM | +₹11 | +₹4 | ₹82 |
| 1 Oct 2026, 2:32 PM | +₹7 | — | ₹78 |
Issue schedule & market details
Acme Universal Safezone 9 IPO key data
These are structured market-data fields. Missing values are left blank rather than estimated.
Issue typeSME
ExchangeBSE SME
Price band₹65 – ₹71
Lot size1,600 shares
Issue size₹35.93 Cr
Open date28 Sep 2026
Close date30 Sep 2026
Listing date6 Oct 2026
Overall subscription15.63× subscribed
Last recorded GMP+₹11
GMP reference price₹82
Quick facts
Acme Universal Safezone 9 IPO FAQs
When does the Acme Universal Safezone 9 IPO open and close?
The opening date is 28 Sep 2026. The closing date is 30 Sep 2026.
When is the Acme Universal Safezone 9 IPO listing date?
The currently recorded listing date is 6 Oct 2026. The timetable can change if the issue schedule is revised.
What is the Acme Universal Safezone 9 IPO price band?
The currently recorded price band is ₹65 – ₹71.
What is the Acme Universal Safezone 9 IPO lot size?
The recorded lot size is 1,600 shares. Review the official issue terms before applying.
What is the Acme Universal Safezone 9 IPO subscription?
Nivata currently records overall issue subscription at 15.63 times. This is not an allotment probability.
This page contains factual IPO schedule, pricing, subscription, listing and GMP information. It does not contain an IPO research article and does not provide a recommendation, rating, target price, valuation conclusion, expected return, listing forecast, allotment probability or a view on whether to participate in the issue.